Vantage Consulting Group’s Bristol-Myers Squibb BMY Stock Holding History

Vantage Consulting Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,655	Closed	-$235K	–	26
2024 Q2	$235K	Buy	5,655 +1,236	+28%	+$55.3K	0.17%	128
2024 Q1	$240K	Sell	4,419 -233	-5%	-$11.9K	0.15%	140
2023 Q4	$239K	Buy	4,652 +844	+22%	+$44.3K	0.16%	146
2023 Q3	$221K	Buy	3,808 +258	+7%	+$15.8K	0.15%	158
2023 Q2	$227K	Sell	3,550 -98	-3%	-$6.57K	0.13%	172
2023 Q1	$253K	Buy	3,648 +576	+19%	+$40.6K	0.14%	148
2022 Q4	$221K	Sell	3,072 -590	-16%	-$44.5K	0.13%	169
2022 Q3	$260K	Buy	3,662 +454	+14%	+$32.9K	0.15%	100
2022 Q2	$247K	Sell	3,208 -127	-4%	-$9.67K	0.14%	132
2022 Q1	$244K	Sell	3,335 -1,281	-28%	-$86K	0.1%	156
2021 Q4	$288K	Buy	4,616 +764	+20%	+$44.8K	0.08%	109
2021 Q3	$228K	Buy	3,852 +486	+14%	+$32K	0.05%	165
2021 Q2	$225K	Buy	+3,366	New	+$219K	0.04%	175
2021 Q1	–	Sell	-1,201	Closed	-$74K	–	304
2020 Q4	$74K	Buy	+1,201	New	+$73.8K	0.01%	282

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vantage Consulting Group's BMY Position: Q3 2024 in Review

Vantage Consulting Group sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 5,655 shares — an estimated $235K sold.

Vantage Consulting Group first reported a position in BMY in Q4 2020 and held it in 14 quarters. The position peaked at $288K in Q4 2021. 2,263 funds tracked by Wall St. Rank hold BMY as of Q3 2024.

Vantage Consulting Group reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
Vantage Consulting Group sold 5,655 Bristol-Myers Squibb shares in Q3 2024, an estimated $235K.
Vantage Consulting Group first reported a position in Bristol-Myers Squibb in Q4 2020 and held it in 14 quarters.
Vantage Consulting Group's Bristol-Myers Squibb position peaked at $288K in Q4 2021.
2,263 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.

Based on Vantage Consulting Group's 13F filing for Q3 2024, filed 14 Nov 2024.